Androgen deprivation for advanced prostate cancer;Androgendeprivation in der therapie des prostatakarzinoms

Urologe - Ausgabe A

Volumn 47, Issue 3, 2008, Pages 270-283

  Heidenreich, A ^a   Pfister, D ^a   Ohlmann, C H ^a   Engelmann, U H ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Adjuvant androgen deprivation; Antiandrogens; Hormone therapy; Intermittent androgen deprivation; LHRH analogues

Indexed keywords

ANDROGEN; ANTIANDROGEN; BICALUTAMIDE; ESTROGEN; GONADORELIN DERIVATIVE; STEROID;

ADVANCED CANCER; ARTICLE; CANCER GROWTH; CANCER LOCALIZATION; CANCER PREVENTION; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CASTRATION; CLINICAL FEATURE; DISEASE DURATION; DRUG EFFICACY; EXPERIMENTAL STUDY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; MONOTHERAPY; ORCHIECTOMY; PATIENT SELECTION; PRACTICE GUIDELINE; PROSTATE CANCER; PROSTATECTOMY;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BONE NEOPLASMS; COMBINED MODALITY THERAPY; ESTROGENS; GONADOTROPIN-RELEASING HORMONE; HUMANS; LYMPHATIC METASTASIS; MALE; NEOPLASM STAGING; ORCHIECTOMY; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS;

EID: 40349113278     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-008-1636-2     Document Type: Article

References (76)

1. Huggins C, Stevens RE Jr, Hodges CV (1941) Studies on prostate cancer. II. The effect of castration on advanced carcinoma of the prostate gland. Arch Surg 43: 209-223
2. Huggins C, Hodges CV (2002) Studies on prostatic cancer. I. The effect of castration of estrogen and of androgen injection on serum phosphatase in metastatic carcinoma of the prostate. J Urol 167: 948-951
3. McLeod DG (2003) Hormonal therapy: historical perspective to future directions. Urology 61(Suppl 1): 3-7
4. Desmond AD, Arnold AJ, Hastie KJ (1988) Subcapsular orchiectomy under local anaesthesia. Technique, results and implications. Br J Urol 61: 143-145
5. Oh WK (2002) The evolving role of estrogen therapy in prostate cancer. Clin Prostate Cancer 1: 81-89
6. Byar DP (1973) Proceedings: the Veterans Administration Co-operative Urological Research Group studies of cancer of the prostate. Cancer 32: 1126-1130
7. Hedlund PO, Ala-Opas M, Brekkan E et al. (2002) Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer - Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scand J Urol Nephrol 36: 405-413
8. Klotz L, McNeill I, Fleshner N (1999) A phase 1-2 trial of diethylstilbestrol plus low dose warfarin in advanced prostate carcinoma. J Urol 161: 169-172
9. Farrugia D, Ansell W, Singh M et al. (2000) Stilboestrol plus adrenal suppression as salvage treatment for patients failing treatment with luteinizing hormone-releasing hormone analogues and orchidectomy. BJU Int 85: 1069-1073
10. Ockrim JL, Lalani EN, Laniado ME et al. (2003) Transdermal estradiol therapy for advanced prostate cancer - forward to the past? J Urol 169: 1735-1737
11. Ockrim JL, Lalani EN, Banks LM et al. (2004) Transdermal estradiol improves bone density when used as a single agent for prostate cancer. J Urol 172: 2203-2207
12. Heidenreich A, Aus G, Bolla M et al. (2008) EAU Guidelines on Prostate Cancer. Eur Urol 53: 68-80
13. Loblaw DA, Virgo KS, Nam R et al. American Society of Clinical Oncology (2007) Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 25: 1596-1605
14. Oefelein MG, Cornum R (2000) Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm. J Urol 164: 726-729
15. Oefelein MG, Feng A, Scolieri MJ et al. (2000) Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology 56: 1021-1024
16. Lin BJ, Chen KK, Chen MT, Chang LS (1994) The time for serum testosterone to reach castrate level after bilateral orchiectomy or oral estrogen in the management of metastatic prostate cancer. Urology 43: 834-837
17. Vogelzang NJ, Chodak GW, Soloway MS et al. (1995) Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group. Urology 46: 220-226
18. Yri OE, Bjoro T, Fossa SD (2006) Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer. Eur Urol 49: 54-58
19. McLeod DG, Zinner N, Tomera K et al. (2001) Abarelix Study Group: A phase 3, multicenter, open-label, randomized study of abarelix versus leuprorelide acetate in men with prostate cancer. Urology 58: 756-761
20. Kawakami J, Morales A (2002) A comprehensive hormonal evaluation in patients with cancer of the prostate on androgen suppression with LHRH agonists. J Urol 167(Suppl 4): 288
21. Heyns CF, Simonin MP, Grosgurin P et al. (2003) Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer. BJU Int 92: 226-231
22. Chu FM, Jayson M, Dineen MK et al. (2002) A clinical study of 22.5 MG LA-2550: a new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 168: 1199-1203
23. Seidenfeld J, Samson DJ, Aronson N (1999) Relative effectiveness and cost- effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Evid Rep Technol Assess (Summ) 4: 1-246
24. Mahler C (1993) Is disease flare a problem? Cancer 72: 3799-3802
25. Bubley GJ (2001) Is the flare phenomenon clinically significant? Urology 58(Suppl): 5-9
26. Sugiono M, Winkler MH, Okeke AA et al. (2005) Bicalutamide versus cyproterone acetate in preventing flare with LHRH analogue therapy for prostate cancer - a pilot study. Prostate Cancer Prostatic Dis 8: 91-94
27. Stricker HJ (2001) Luteinizing hormone-releasing hormone antagonists in prostate cancer. Urology 58(Suppl 2A): 24-27
28. Trachtenberg J, Gittleman M, Steidle C et al. (2002) A phase 3, multicentre, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol 167: 1670-1674
29. Iversen P (2002) Antiandrogen monotherapy: indications and results. Urology 60(Suppl 3A): 64-71
30. Chodak GW, Keane T, Klotz L (2002) Critical evaluation of hormonal therapy for carcinoma of the prostate. Urology 60: 201-208
31. Mahler C, Verhelst J, Denis L (1998) Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer. Clin Pharmacokinet 34: 405-417
32. Narayana AS, Loening SA, Culp DA (1981) Flutamide in the treatment of metastatic carcinoma of the prostate. Br J Urol 53: 152-153
33. Sogani PC, Vagaiwala MR, Whitmore WF Jr (1984) Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy. Cancer 54: 744-750
34. Lundgren R (1987) Flutamide as primary treatment for metastatic prostatic cancer. Br J Urol 59: 156-158
35. Delaere KP, Van Thillo EL (1991) Flutamide monotherapy as primary treatment in advanced prostatic carcinoma. Semin Oncol 18(Suppl 6): 13-18
36. Pavone Macaluso M (1994) Flutamide monotherapy versus combined androgen blockade in advanced prostate cancer. Interim report of an Italian multicentre, randomized study. SIU 23rd Congress, pp 354
37. Boccon-Gibod L, Fournier G, Bottet P et al. (1997) Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. Eur Urol 32: 391-395
38. Iversen P, Tyrrell CJ, Kaisary AV et al. (2000) Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of follow-up. J Urol 164: 1579-1582
39. See WA, Wirth MP, McLeod DG et al. (2002) Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J Urol 168: 429-435
40. Iversen P, Tyrrell TLJ, Vaage S et al. (2002) A randomised comparison of bicalutamide (Casodex) 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study No 6. Eur Urol 42: 204-211
41. Tyrrell CJ, Kaisary AV, Iversen P et al. (1998) A randomised comparison of Casodex (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 33: 447-456
42. Kolvenbag GJ, Nash A (1999) Bicalutamide dosages used in the treatment of prostate cancer. Prostate 39: 47-53
43. Kaisary AV, Iversen P, Tyrrell CJ et al. (1999) Is there a role for antiandrogen monotherapy in patients with metastatic prostate cancer? Prostate Cancer Prostatic Dis 4: 196-203
44. Iversen P, Tyrrell CJ, Kaisary AV et al. (1998) Casodex (bicalutamide) 150 mg monotherapy compared with castration in patients with previously untreated non-metastatic prostate cancer: results from two multicentre randomized trials at a median follow-up of 4 years. Urology 51: 389-396
45. Fourcade RO, Chatelain C, Poterre M et al. (1998) An open multicentre randomized study to compare the effect and safety of 'Casodex' (bicalutamide) 150 mg monotherapy with castration plus nilutamide in metastatic prostate cancer. Eur Urol 33(Suppl 1): 88-349
46. Boccardo F, Barichello M, Battaglia M et al. (2002) Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial. Eur Urol 42: 481-490
47. Wirth MP, See WA, McLeod DG et al. Casodex Early Prostate Cancer Trialists' Group (2004) Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer programme at median followup of 5.4 years. J Urol 172: 1865-1870
48. McLeod DG, Iversen P, See WA et al. Casodex Early Prostate Cancer Trialists' Group (2006) Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 97: 247-254
49. Seidenfeld J, Samson DJ, Aronson N et al. (1999) Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Evidence Report/Technology Assessment N0. 4. AHCPR Publication No. 99-E0012. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, US Department of Health and Human Services, May 1999
50. Prostate Cancer Trialists' Collaborative Group (2000) Maximum androgen blockade in advanced prostate cancer: an overview of the randomized trials. Lancet 355: 1491-1498
51. Schmitt B, Bennett CL, Seidenfeld J et al. (2000) Maximal androgen blockade for advanced prostate cancer. Cochrane Database Syst Rev 2: D001526
52. Schmitt B, Wilt TJ, Schellhammer PF et al. (2001) Combined androgen blockade with non-steroidal antiandrogens for advanced prostate cancer: a systematic review. Urology 57: 727-732
53. Samson DJ, Seidenfeld J, Schmitt B et al. (2002) Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 95: 361-376
54. Collette L, Studer UE, Schroder FH et al. (2001) Why phase III trials of maximal androgen blockade versus castration in M1 prostate cancer rarely show statistically significant differences. Prostate 48: 29-39
55. Jordan WP Jr, Blackard CE, Byar DP (1977) Reconsideration of orchiectomy in the treatment of advanced prostatic carcinoma. South Med J 70: 1411-1413
56. Medical Research Council Prostate Cancer Working Party Investigators Group (1997) Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol 79: 235-246
57. Messing EM, Manola J, Sarosdy M et al. (1999) Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341: 1781-1788
58. Bayoumi AM, Brown AD, Garber AM (2000) Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. J Natl Cancer Inst 292: 1731-1739
59. Studer UE, Whelan P, Albrecht W et al. (2006) Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 24: 1868-1876
60. Nair B, Wilt T, MacDonald R, Rutks I (2002) Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database Syst Rev 1: CD003506
61. Cheng L, Zincke H, Blute ML et al. (2001) Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer 91: 66-73
62. Bolla M, Collette L, Blank L et al. (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study) a phase III randomized trial. Lancet 360: 103-106
63. Pilepich MV, Winter K, Lawton CA et al. (2005) Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61: 1285-1290
64. Hanks GE, Pajak TF, Porter A et al. Radiation Therapy Oncology Group (2003) RTOG 92-02: Phase III trial of longterm adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. J Clin Oncol 21: 3972-3978
65. Bruchovsky N, Rennie PS, Coldman AJ et al. (1990) Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 50: 2275-2282
66. Pether M, Goldenberg SL (2004) Intermittent androgen suppression. BJU Int 93: 258-261
67. Bouchot O, Lenormand L, Karam G et al. (2000) Intermittent androgen suppression in the treatment of metastatic prostate cancer. Eur Urol 38: 543-549
68. Hussain M, Tangen CM, Higano C et al. (2006) Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 24: 3984-3990
69. Lane TM, Ansell W, Farrugia D et al. (2004) Long-term outcomes in patients with prostate cancer managed with intermittent androgen suppression. Urol Int 73: 117-122
70. De Leval J, Boca P, Yousef E et al. (2002) Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial. Clin Prostate Cancer 1: 163-171
71. Bruchovsky N, Klotz L, Crook J, Goldenberg SL (2007) Locally advanced prostate cancer-biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy. Cancer 109: 858-867
72. Thunn UW, Kurek R, Kienle E et al. (2004) Intermittent is as effective as continuous androgen deprivation in patients with PSA relapse after radical prostatectomy. J Urol 171: 384-1458
73. Kliesch S, Behre HM, Roth S (1997) Rationale Therapie der Hitzewallungen unter Hormonentzugsbehandlung bei Patienten mit fortgeschrittenem Prostatakarzinom. Dtsch Med Wochenschr 122: 940-945
74. Spetz AC, Hammar M, Lindberg B et al. (2001) Prospective evaluation of hot flashes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate. J Urol 166: 517-520
75. Langenstroer P, Kramer V, Cutting B et al. (2005) Parenteral medroxyprogesterone fort he management of luteinizing hormone releasing hormone induced hot flashes in men with advanced prostate cancer. J Urol 174: 642-645
76. Widmark A, Fossa SD, Lundmo P et al. (2003) Does prophylactic breast irradiation prevent antiandrogen-induced gynecomastia? Evaluation of 253 patients in the randomized Scandinavian trial SPCG-7/SFUO-3. Urology 61: 145-151